Understand the source comparison
VIP Half-Life vs. Other Research Peptides: Comparison
Understanding VIP's half-life in context requires comparison to other commonly researched peptides with varying stability profiles. VIP (vasoactive intestinal peptide) 1–2 minutes DPP-IV and NEP cleavage at N-terminus and internal sites 12–24 months at −20°C 4
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding VIP's half-life in context requires comparison to other commonly researched peptides with varying stability profiles.
- VIP (vasoactive intestinal peptide)
- 1–2 minutes
- DPP-IV and NEP cleavage at N-terminus and internal sites
- 12–24 months at −20°C
- 48–72 hours maximum; significant loss after 24 hours
- Extremely short half-life requires continuous infusion or modified analogs for sustained effect
- GLP-1 (glucagon-like peptide-1)
- 2–3 minutes
- DPP-IV cleavage at Ala2 position
- 12–18 months at −20°C
- 72 hours; stable up to 7 days with protease inhibitors
- Similar rapid degradation to VIP; clinical use relies on DPP-IV-resistant analogs (semaglutide, liraglutide)
- BPC-157 (body protection compound)
- 4–6 hours (estimated)
- Generalized proteolysis; exact pathway not fully characterized
- 24+ months at −20°C
- 14–21 days at 4°C; one of the most stable peptides in solution
- Substantially longer half-life than VIP; suitable for daily or twice-daily dosing
- TB-500 (Thymosin Beta-4 fragment)
- 2–3 hours
- Nonspecific serum peptidase degradation
- 18–24 months at −20°C
- 7–14 days at 4°C
- Moderate half-life; weekly administration feasible for research protocols
- Melanotan II
- 1–2 hours
- Hepatic metabolism and renal clearance
- 30+ days at 4°C due to cyclic structure
- Cyclized structure provides protease resistance; much longer solution stability than linear peptides
- Insulin
- 4–6 minutes (IV); 1–2 hours (SC depot)
- Insulin-degrading enzyme (IDE) and hepatic clearance
- 24–36 months at 4°C (pharmaceutical formulations)
- 28 days at 4°C after first use (per FDA labeling)
- Rapid clearance when administered IV; subcutaneous depot extends effective duration
- VIP's 1–2 minute half-life places it among the most rapidly degraded bioactive peptides in human physiology. Only a handful of signaling peptides. Substance P, bradykinin, angiotensin II. Share comparably short circulation times. The practical consequence is that VIP research protocols require either real-time measurement of biological endpoints (within 5–10 minutes of administration) or continuous infusion systems that maintain steady-state concentrations. Single-dose studies with VIP are methodologically limited unless modified analogs are used.